PEGS Boston 2021 Recap Series

Rapid Novor Continues to Empower Researchers through Protein Sequencing Advances

With some exciting news to share, we were eager to present about how our company is advancing antibody discovery thanks to our next generation protein sequencing at the PEGS Summit last week. And it seems that many people were anticipating our talk as well, as over 70 people attended our presentation!

Anthony Stajduhar – Landing on the Moon with Mass Spectrometry: Polyclonal Sequencing with Only Proteomics

Anthony, our Director of International Business Development, discussed our antibody protein sequencing technology, the services we offer (REmAb®, REpAb® and NovorIg™), and their applications such as advancing antibody therapeutic discovery and development, decoding the immune response in vaccinology studies, and monitoring relapse in patients suffering from cancers like multiple myeloma (MM). In his presentation, Anthony hinted at some exciting data stemming from our REpAb® platform, relying only on proteomics and machine learning. [The official announcement about this world’s first achievement went out today!]

Rapid Novor’s decades of experience in proteomics, bioinformatics and BIG DATA processing enabled this most recent REpAb® breakthrough . Our core technology, REmAb®, uses mass spectrometry to sequence the primary amino acid sequence of antibodies, without needing to have access to a cell line, or to genomic or transcriptomic data. With the help of protein de novo sequencing, we have successfully sequenced over 3000 proteins, helping researchers around the world reduce their target product variability, facilitate the engineering of therapeutic candidates, ensure the recovery of lost cell lines, and secure countless antibody supply chains. With the development of REpAb® and NorvorIg™, we can reach our goal of decoding immunity.

Stay tuned for more info!

After his talk, many questions centered around how we pair our chains, but we’re not ready to reveal our secrets! However, we welcome your challenging projects so make sure to contact us to discuss how we can help you reach your antibody discovery and development pipeline goals faster. And stay tuned for more info!

Next in the PEGS Boston 2021 Recap Series…

Stay tuned, we’ll be talking about Trispecific Antibodies, AIDS, Cancer and mAb sequencing by proteomics. Sign up for our Rapid Insights to get a recap of the whole series.

Sign up for the newsletter.

Sign up for the next webinar.

Whitepaper: Prevalence of Secondary Light Chains

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 3000 antibodies and we are eager to help you.